



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts**

**Public declaration of interests**

I, **Birgit Geoerger**

**Organisation/Company:** Institut Gustave-Roussy

**Country:** France

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
02/2006-(current)	Novartis, Roche, Boehringer Ingelheim, Pharma Mar, Celgene, Bayer, Onyx, BMS, AZD	Gimatecan, LDE225, Tarceva, Herceptin, Nutlins, Afitinib, BIBF1120, BI6729, Aplidin, Abraxane, Revlimid, Cobimetinib, Onartuzumab, AKT inhibitors, ruxolinitib, CD-22/79b-ADC, regorafenib, carfilzomib, atezoluzumab, nivolumab, FAP-IL2v, PCV (RO7198457), aCD40, FAP-4-1BBB-ligand, TIGIT	pediatric solid tumors

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

## 2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
02/2011-(current)	Novartis, MSD, GSK, BMS, Celgene, Roche, Bayer, Boehringer Ingelheim, LOXO Oncology, Epizyme	LDE225, dalotuzumab, ridaforolimus, dabrafenib, ipilimumab, LDK378, LEE011, abraxane, pembrolizumab, cobimetinib, atezolizumab, regorafenib, afatinib, tazemetostat, larotrectinib, LOXO-195	pediatric solid tumors

## 2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2001-(current)	Various (Investigator in all phase I and various agents pediatric solid tumors phase II trials open at Institut Gustave Roussy)	Various agents	pediatric solid tumors

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

No interest declared

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

**"EMA Activities"** encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

**"Confidential Information"** means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

**"Confidential Documents"** mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

<b>Full Name:</b>	Birgit Geoerger
<b>Date:</b>	2020-04-14

*For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template*